
Labcorp Holdings Inc.
NYSE•LH
CEO: Mr. Adam H. Schechter
セクター: Healthcare
業種: Medical - Equipment & Services
上場日: 1990-03-29
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
連絡先情報
時価総額
$22.94B
PER (TTM)
26.0
37.7
配当利回り
1.0%
52週高値
$293.72
52週安値
$209.38
52週レンジ
順位21Top 7.6%
6.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$3.52B+0.00%
直近4四半期の推移
EPS
$2.00+0.00%
直近4四半期の推移
フリーCF
$490.30M+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Nine Month Revenue Growth Nine months revenues reached $10.44B USD, marking an 7.8% increase driven by 4.6% organic growth.
Quarterly Net Earnings Surge Net earnings attributable to LHI for the quarter totaled $261.1M USD, reflecting a strong 54.2% increase.
Operating Cash Flow Improvement Net cash provided by operating activities was $1.03B USD for nine months, showing a 27.0% increase.
Shareholders' Equity Increase Total shareholders' equity grew to $8.70B USD as of September 30, 2025, supported by retained earnings.
リスク要因
Ongoing Litigation Exposure Company faces numerous legal actions, including False Claims Act suits and civil investigative demands, seeking indeterminate damages.
Rising Interest Expense Interest expense increased 16.7% for nine months due to higher weighted-average rates and increased debt outstanding.
Acquisition Integration Uncertainty YTD 2025 acquisitions totaled $324.0M cash spent; realizing expected synergies and managing integration remains a risk.
Regulatory Environment Changes New OBBBA tax law enacted July 2025 requires ongoing assessment of potential impacts on utilization and reimbursement.
見通し
Credit Facility Capacity Secured Senior revolving credit facility amended in June 2025, providing up to $1.0B USD in available borrowings expiring in 2030.
Future Acquisitions Planned Anticipates closing pending acquisitions from CHS and Empire City in Q4 2025 and Q1 2026, totaling up to $445.0M.
Share Repurchase Authorization Board maintains authorization to purchase up to $1,055.4M maximum value of Common Stock with no expiration date.
Sufficient Liquidity Expected Believes current cash flows and credit facility availability provide sufficient liquidity for anticipated short and long-term needs.
同業比較
売上高 (TTM)
TEVA$17.26B
LH$13.95B
DGX$11.04B
粗利益率 (最新四半期)
INCY90.9%
87.4%
BIIB78.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TEVA | $39.46B | 28.1 | 20.1% | 42.7% |
| NTRA | $29.22B | -93.7 | -25.1% | 10.1% |
| BIIB | $28.71B | 22.2 | 7.3% | 23.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.7%
緩やかな成長
4四半期純利益CAGR
-8.2%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月27日
EPS:-
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年10月31日|売上高: $3.56B+8.6%|EPS: $3.14+55.4%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月1日|売上高: $3.53B+9.5%|EPS: $2.86+17.2%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年4月29日|売上高: $3.35B+5.3%|EPS: $2.54-6.3%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月25日|売上高: $13.01B+7.0%|EPS: $8.89+85.2%予想を上回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年10月29日|売上高: $3.28B+7.4%|EPS: $2.02-4.7%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月2日|売上高: $3.22B+6.2%|EPS: $2.44+14.6%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年4月30日|売上高: $3.18B+4.6%|EPS: $2.71+12.4%予想を下回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月26日|売上高: $12.16B+2.5%|EPS: $4.80-65.8%予想を下回る